Cancer Stem Cell News Volume 11.12 | March 30 2022


    2022-03-30 | CSCN 11.12

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 11.12 – 30 March, 2022

    FOXK2 Promotes Ovarian Cancer Stemness by Regulating the Unfolded Protein Response Pathway

    Through comparative chromatin state and gene expression analyses in ovarian CSCs vs. non-CSCs, researchers identified FOXK2 as a highly expressed stemness-specific transcription factor in ovarian cancer.
    [Journal of Clinical Investigation]

    Full ArticleGraphical Abstract

    Survey results on the insights and hurdles of CRISPR genome editing.
    PUBLICATIONSRanked by the impact factor of the journal

    FOSL1 Promotes Proneural-to-Mesenchymal Transition of Glioblastoma Stem Cells via UBC9/CYLD/NF-κB Axis

    Researchers reported that FOSL1, a component of AP-1 transcription factor complexes, was a key player in regulating proneural to mesenchymal transition. FOSL1 was predominantly expressed in the mesenchymal subtype, but not the proneural subtype of glioblastoma stem cells.
    [Molecular Therapy]

    AbstractGraphical Abstract

    Low-Temperature Plasma-Activated Medium Inhibited Proliferation and Progression of Lung Cancer by Targeting the PI3K/Akt and MAPK Pathways

    Scientists explored the effect of the plasma-activated medium on lung cancer cells in vitro and in vivo by using a 3D cell culture model.
    [Oxidative Medicine and Cellular Longevity]

    Full Article

    Exosomal DEK Removes Chemoradiotherapy Resistance by Triggering Quiescence Exit of Breast Cancer Stem Cells

    Scientists identified and isolated chemoradiotherapy-resistant CSCs in quiescent state with high capacity of tumor-initiation and tumorsphere formation from three types of breast tumors in mice.


    TGFβ Selects for Pro-Stemness over Pro-Invasive Phenotypes during Cancer Cell Epithelial–Mesenchymal Transition

    Whether TGFβ promoted stemness and invasiveness simultaneously via epithelial-mesenchymal transition remains unclear. The authors established a breast cancer cell model expressing red fluorescent protein under the E-cadherin promoter.
    [Molecular Oncology]

    AbstractFull Article

    Local Anesthetic Levobupivacaine Inhibits Stemness of Osteosarcoma Cells by Epigenetically Repressing MAFB Though Reducing KAT5 Expression

    Scientists identified that the treatment of levobupivacaine suppressed the proliferation of osteosarcoma cells in vitro, and suggested that it might act as a potential therapeutic candidate for osteosarcoma by targeting CSCs.

    Full Article

    A Bioinspired Redox-Modulating Copper(II)–Macrocyclic Complex Bearing Non-Steroidal Anti-Inflammatory Drugs with Anti-Cancer Stem Cell Activity

    Investigators reported a biologically stable copper(II) complex based on the active site of type I copper electron transport proteins.
    [Dalton Transactions]

    Full ArticleGraphical Abstract

    Suppressive Effect of α-Mangostin for Cancer Stem Cells in Colorectal Cancer via the Notch Pathway

    Scientists evaluated the selective inhibition of α-mangostin on CSCs in colorectal cancer and the suppressive effect on 5-fluorouracil-induced CSCs.
    [BMC Cancer]

    Full Article

    Ubiquitin-Specific Protease 1 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Doxorubicin by Ubiquitinated Proliferating Cell Nuclear Antigen–Mediated Attenuation of Stemness

    Researchers investigated the effect of ubiquitin-specific protease 1 depletion with chemotherapeutant doxorubicin on hepatocellular carcinoma cells.
    [Anti-Cancer Drugs]


    Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart

    Cancer Stem Cell Markers for Urinary Carcinoma

    At present, the isolation and identification of CSCs from many solid tumors are still quite difficult, mainly due to the lack of specific molecular markers of CSCs. The authors summarize CSC surface markers and functional markers in the urinary system.
    [Stem Cells International]

    Full Article


    OncoTEX Receives Notice of Allowance for Patent in Korea regarding Ovarian Cancer-Fighting Drug OxaliTEX

    OncoTEX, Inc. announced its novel cancer-fighting drug candidate, OxaliTEX, has received a notice of allowance for patent in Korea.
    [OncoTEX, Inc. (GlobeNewswire, Inc.)]

    Press Release


    13th Online Dutch Stem Cell Meeting

    April 16, 2022

    > See All Events


    Postdoctoral Position – Tumor Heterogeneity

    Luxembourg Institute of Health – Strassen, Luxembourg

    Postdoctoral Scientist – Translational Oncogenomics Group

    CRUK Manchester Institute – Manchester, England, United Kingdom

    Principal Scientific Researcher – Cell and Tissue Genomics

    Genentech, Inc. – South San Francisco, California, United States

    Senior Associate Scientist – Biology

    Gilead Sciences – Foster City, California, United States

    Postdoctoral Scholar – Cancer Cell Identity

    Oregon Health and Science University – Portland, Oregon, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter